IHCP *bulletin*

INDIANA HEALTH COVERAGE PROGRAMS BT201104 MARCH 1, 2011

Changes to the Preferred Drug List

Changes to the Preferred Drug List (PDL) were made at the February 18, 2011, Drug Utilization Review (DUR) Board meeting. These decisions are based on the recommendations from the Therapeutics Committee meeting held February 4, 2011. Please refer to the table on the next page for a summary of these changes. The changes are effective April 1, 2011.

The PDL can be accessed online at the Indiana Pharmacy Benefit Manager Web site (http://www.indianapbm.com) under Pharmacy Services. Notice of the DUR Board meetings and agendas are posted on the Family and Social Services Administration (FSSA) Web site (http://www.state.in.us/fssa). Click “More Events” near the middle of the page to access the events calendar. Information about the Therapeutics Committee is available online at the Indiana Pharmacy Benefit Manager Web site (http://www.indianapbm.com).

Please direct prior authorization requests and questions about the PDL to the Affiliated Computer Services (ACS) Clinical Call Center at 1-866-879-0106. Please direct questions about this bulletin to HP Customer Assistance at (317) 655-3240 in the Indianapolis local area, or toll-free at 1-800-577-1278.

Continue

Approved changes to the PDL effective April 1, 2011

Drug class	Drug	PDL status
Antiviral Monoclonal Antibodies	Synagis	Non-preferred with PA. Statement on the bottom of the PA form will read as follows: Usual dosage is five (5) monthly injections during RSV season of November 1 through March 31 Implementation date of May 1, 2011
Leukotriene Receptor Antagonists	zafirlukast	Non-preferred with same step edit as Accolate
Beta Adrenergics and Corticosteroids	Dulera	Non-preferred
Oral Inhaled Glucocorticoids	budesonide suspension	Preferred for children 3 years old and younger Non-preferred for children 4 years old and older Quantity limit of 120 mls/mo for the 0.25 mg/2 ml vial
Oral Inhaled Glucocorticoids	Pulmicort Respules	Non-preferred with age limit of 4 years old and older Quantity limit of 120 mls/mo for the 0.25 mg/2 ml vial
Pulmonary Antihypertensives – PDE 5 Inhibitors	Adcirca	Preferred with SmartPA™ criteria
Pulmonary Antihypertensives – PDE 5 Inhibitors	Revatio	Preferred with SmartPA criteria
Cephalosporins – 3rd Generation	Cedax suspension	Non-preferred for 180 mg/5 ml concentration (new strength)
Oral Non-systemic Antifungals	clotrimazole troches	Preferred
Oral Non-systemic Antifungals	nystatin suspension and tablets	Preferred
Oral Non-systemic Antifungals	Oravig	Non-preferred
Angiotensin Receptor Blockers	losartan	Preferred with current quantity limit and step edit
Angiotensin Receptor Blockers	Cozaar	Non-preferred with current quantity limit and step edit
ARBs with CCBs and Diuretics	Tribenzor	Non-preferred with step edit “trial of an ARB, CCB or diuretic within the past 90 days”
ARBs with Diuretics	losartan/ hydrochlorothiazide	Preferred with current step edit
ARBs with Diuretics	Hyzaar	Non-preferred with current step edit
Bile Acid Sequestrants	Welchol tablets and suspension	Non-preferred with SmartPA criteria
Lipotropics	Simcor	Preferred for 500 mg/40 mg and 1,000 mg/40 mg formulations (new strengths)
Antimigraine Preparations	Alsuma	Not covered
Antimigraine Preparations	naratriptan	Preferred with quantity limit of 9 tabs/mo

Continue

Drug class	Drug	PDL status
MS Agents	Ampyra	Preferred with quantity limit of 2 tabs/day and the following PA criteria: For initial authorization – patient must have a diagnosis of MS and a prescription written by a neurologist; approval for 3 months 2nd authorization – Neurologist documentation of improvement in gait; approval for 1 year Subsequent authorizations – Neurologist documentation of impression of continued clinical benefit in gait; approval for 1 year
MS Agents	Gilenya	Non-preferred with quantity limit of 1 cap/day
MS Agents		Step edit for all non-preferred agents: "trial of at least 1 preferred agent written by, or in consultation with, a neurologist within the past 12 months"

Questions?

If you have questions about this bulletin, please contact Customer Assistance at (317) 655-3240 in the Indianapolis local area or toll-free at 1-800-577-1278.